Drug Trial Radar · NCT03352726
A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects
Last checked: Nov 19, 2026Latest source record: Jul 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Nov 24, 2017
Primary completion
Jun 29, 2018
Study completion Jun 29, 2018
Sponsor
- Lead sponsor
- DBV TechnologiesIndustry
- Sponsor type
- Industry
- First posted
- Nov 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aims to assess the biological potency of the In-House Reference Preparation (IHRP) of peanut allergens extract by a quantitative Skin Prick Test (SPT) method in peanut-allergic subjects.
Conditions
- Peanut Allergy
Interventions
DBV712 IHRPDrug
DBV712 Solution for Skin Prick Test
Primary outcomes
What the sponsor says the trial is designed to measure.
- Biological potency of the In-House Reference peanut proteins extract (DBV712-IHRP) in arbitrary Biological Units (BU)Time frame: 1 day to 2 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas
Children's Hospital Colorado
Aurora, Colorado
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.